Market Overview:
Epidermolysis bullosa (EB) is a rare genetic skin disorder characterized by easy blistering of the skin and mucous membranes. The blisters are caused by minor injury or friction and may appear spontaneously. EB spectrum ranges from very mild to severe forms affecting multiple internal organs. Advancement in digital health and smart healthcare technologies has enabled remote monitoring of EB patients and development of novel targeted treatment options.
The global Epidermolysis Bullosa Market is estimated to be valued at US$ 3,429.30 Mn in 2023 and is expected to exhibit a CAGR of 11.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Get more insights on this topic: https://www.coherentmarketinsights.com/market-insight/epidermolysis-bullosa-therapeutics-market-2214
Market key trends:
One of the key trends in EB market is the rising adoption of regenerative medicine approaches for developing novel treatment options. EB causes fragility of tissues including skin, which can lead to blisters and wounds. Regenerative medicines such as cell therapy aim to replace or regenerate human cells, tissues or organs to restore or establish normal function. Promising cell therapy candidates such as mesenchymal stem cells are being evaluated which secrete therapeutic factors promoting wound healing in EB patients.
SWOT Analysis
Strength: The market has seen increased research and development activities focused on developing new treatment options such as gene therapies which gives hope to patients. Research is also being conducted to examine the underlying genetic causes which can help develop targeted treatment strategies.
Weakness: EB has a very low diagnosis rate and awareness about the condition is still low. Lack of approved treatment options make management of symptoms challenging. Gene therapies under development also have high treatment costs.
Opportunity: Growing research on advanced treatment modalities like gene therapies, stem cell therapies provide scope for more effective treatments. Increasing awareness campaigns by patient advocacy groups can help improve early diagnosis rates.
Threats: High research & development costs associated with new drug development can delay market entry. Regulatory approval process is stringent for new therapies in rare diseases. Limited patient pool also poses challenges to clinical trial recruitment.
Key Takeaways
The global Epidermolysis Bullosa market is expected to witness high growth, exhibiting CAGR of 11% over the forecast period, due to increasing research on advanced treatment strategies like gene therapies and stem cell therapies.
Regional analysis:
North America is expected to dominate the EB market during the forecast period due to growing research activities supported by increased funding. The US contributes to the largest share due to presence of major players, advanced healthcare facilities and high awareness. Europe is also among the lucrative markets due presence of key market players and support from government & private organizations for orphan drug development.
Key players:
Key players operating in the Epidermolysis Bullosa market are Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim/Shionogi. These players are focused on developing advanced novel treatment therapies as existing management options only provide symptomatic relief and do not cure the condition.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
